Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Conditions
Ovarian Neoplasms
What is the purpose of this trial?
This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (<1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Female
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Cancer International Research Group
- Dates:
- January 2009
- Last Updated:
- January 28, 2013
- Study HIC#:
- 1002006324
Clinicaltrials.gov ID: NCT00718523
For more information about this trial, contact:
Investigator
Thomas Rutherford, MD, PhD
Principal Investigator
